Novartis' Reclast gets FDA blessing

Score one for Novartis. Its once-yearly treatment for post-menopausal osteoporosis, Reclast, now has the FDA's blessing. Already approved in the U.S. and E.U. for treatment of Paget's bone disease, the drug is expected to win approval in Europe within three months.

It's a big deal for the drug maker: Analysts expect sales of Reclast to reach $1 billion in sales. As a once-yearly treatment, it doesn't have to be taken every day as other osteoporosis remedies do, and a three-year trial showed a 70 percent decrease in certain types of fractures due to the disease. With the Baby Boom in menopausal territory, the drug has a huge potential market. 

- see this press release
- read the AFX report for more 

Related Articles:
Novartis shares slide after Zelnorm gets yanked. Report
Novartis pays big for roster of new vaccines. Report


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.